Genesis Biopharma has merged with Lion Biotechnologies and says its tumor-infiltrating lymphocyte (TIL) technology can offer higher potency cancer drugs with lower manufacturing costs.
The US National Institutes of Health (NIH) announced this week that the famous HeLa genomic sequence data will continue to be available for scientists worldwide, though they will have to apply for access to the data.
Making better CHO cell lines for biomanufacturing may soon be a more precise task according to the team behind the draft Chinese hamster genome published last week.
A new genetically modified strain of E. Coli cells could create enough protein for downstream production without the need for the challenging endotoxin removal steps that are currently employed.
Recent reports of a 'clinical trial' assessing 'stem cells' for the treatment of AMD are wrong say the Japanese researchers trying to transform somatic cells into retinal pigment epithelium (RPE) cells for transplant.
Keeping up with the latest technology news is a must for biomanufacturers according to an MIT Professor who told BioPharma-Reporter.com new advances in microtechnologies could help address process development challenges.
CMO ProBioGen says its GlymaxX ADCC antibody enhancement technology can be adapted to any biomanufacturing cell line and will attract both Big and Small Pharma.
GE Healthcare says new cell science lab in Wales will save drugmakers time and money and create more accurate alternatives to animal-based drug toxicity testing models.
Cobra Biologics claims a new micro bioreactor technology it has adopted can cut three months off cell line development timelines and facilitate faster production scale-up.
